Rohan Sabloak

Rohan Sabloak

Auto-generated profile, based on publicly available information

Rohan Sabloak

Department of Medical Profession, Faculty of Medicine Sriwijaya University Palembang South Sumatra Indonesia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in World Neurosurgery
Verified
Journal Article
Open access
WFWalter Fagundes
Walter Fagundes
AAAisha Rizwan Ahmed
Aisha Rizwan Ahmed
YSYasmin Picanço Silva
Yasmin Picanço Silva
OSOguz Kagan Sahin
Oguz Kagan Sahin
RJRabbia Jabbar
Rabbia Jabbar
HBHerika Negri Brito
Herika Negri Brito
Ventriculoperitoneal shunt (VPS) is the standard treatment for hydrocephalus in neonates and infants, but is commonly complicated by shunt infections. Antibiotic-impregnated catheters (AICs) have been introduced to mitigate infection risk; however, their effectiveness remains uncertain. We conducted a systematic review and meta-analysis comparing outcomes in neonates and infants who underwent VPS with and without AICs. Primary outcomes included shunt infection risk, time to first infection, and infections caused by gram-positive cocci and gram-negative rods. Pooled odds ratios (ORs), mean differences, and 95% confidence intervals (CIs) were calculated using random-effects models. Seven studies encompassing 1,009 patients were included. The use of AICs was associated with a significant three-fold reduction in overall shunt infection risk compared to standard catheters (OR 0.27; 95% CI 0.15-1.03; P < 0.01; I² = 0%). Subgroup analysis showed significant infection risk reduction in infants (OR 0.29; 95% CI 0.12-0.67; P = 0.004) and neonates (OR 0.26; 95% CI 0.11-0.62; P < 0.01). AICs led to a significant decrease in gram-positive cocci infections (OR 0.20; 95% CI 0.06-0.69; P = 0.01) but not gram-negative rod infections. The time to first infection was significantly prolonged in the AIC group (mean difference 4.6 months; 95% CI 2.2-6.9; P < 0.01). Lower infection risk persisted at 6 months and beyond. AICs substantially reduce infection risk and delay infection onset in neonates and infants undergoing VPS, particularly for gram-positive bacteria. Routine use is recommended.

29 May 2026 in Substance use & addiction journal
Verified
Journal Article
Closed access
DBDouglas Barroso
Douglas Barroso
MKMartin Kotochinsky
Martin Kotochinsky
MAMateus Rodrigues Alessi
Mateus Rodrigues Alessi
WAWellgner Fernandes Oliveira Amador
Wellgner Fernandes Oliveira Amador
DGDiogo Carrazzoni Godoi
Diogo Carrazzoni Godoi
ATAlvaro Texeira
Alvaro Texeira
Background: Stimulant use disorder (StUD), particularly involving cocaine and amphetamines, is associated with significant cognitive impairments that impede recovery and increase relapse risk. Atomoxetine, a selective norepinephrine reuptake inhibitor, has been proposed as a potential treatment given its role in enhancing executive function and its established efficacy in attention-deficit/hyperactivity disorder (ADHD). This systematic review aimed to evaluate the efficacy, cognitive, and mood effects of atomoxetine compared with placebo in individuals with StUD. Methods: A comprehensive literature search of PubMed, Cochrane CENTRAL, and Embase databases was conducted to identify randomized controlled trials (RCTs) evaluating atomoxetine for StUD. Eligible studies compared atomoxetine with placebo and assessed outcomes related to cognition (attention and response inhibition), stimulant use or abstinence, mood symptoms, and safety. Data were extracted and synthesized qualitatively due to methodological heterogeneity across studies. Results: Nine RCTs met the inclusion criteria. Findings on cognitive outcomes were inconsistent: Some studies reported improvements in attentional bias and inhibitory control, while others showed no significant effects. Atomoxetine did not significantly reduce stimulant use, craving, or sustain abstinence compared with placebo. Limited mood-related benefits were observed, particularly among male participants, although results were variable. Across studies, atomoxetine was well tolerated, with most adverse events mild and transient. Conclusion: Despite a compelling neurobiological rationale and evidence of modest cognitive and mood benefits, atomoxetine has not demonstrated consistent efficacy as a monotherapy for StUD. Its favorable safety profile may warrant further investigation in carefully defined populations, such as individuals with comorbid ADHD or in combination with behavioral interventions.

11 July 2026 in Medcomm – Biomaterials and Applications
Verified
Journal Article
Open access
PDF file
Tungki Pratama UmarTungki Pratama Umar
Tungki Pratama Umar
DADessy Agustini
Dessy Agustini
SHSandy Hasan
Sandy Hasan
RSRohan Sabloak
Rohan Sabloak
Stromal cell‐derived factor‐1α (SDF‐1α) is a potent stem cell recruitment chemokine that can promote angiogenesis, particularly when delivered via gene‐activated scaffolds (GAS). This systematic review and meta‐analysis synthesized in vitro evidence on the angiogenic potential of SDF‐1α GAS. Four databases were utilized to search for eligible studies, comprising investigations that examined the in vitro effects of SDF‐1α GAS on angiogenesis‐related outcomes compared with gene‐free scaffolds. Data on gene expression, protein levels, and endothelial formation were extracted. Meta‐analyses were conducted using random or fixed‐effect models, expressed as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). Risk of bias was assessed using the Quality Assessment Tool for In Vitro Studies (QUIN) tool. Eight studies were included. Pooled analysis demonstrated SDF‐1α GAS efficacy to significantly increase SDF‐1α gene expression (SMD = 1.20; 95% CI = 0.13–2.27; p = .03), fold‐change of the gene (MD = 12.48; 95% CI = 10.33–14.64; p < .0001), and protein production (MD = 0.29 ng/mL; 95% CI = 0.14–0.43 ng/mL; p = .0001). Most studies showed a moderate risk of bias. Based on in vitro studies, SDF‐1α GAS activity is associated with significant elevation of SDF‐1α gene expression and protein quantity, although it did not exhibit significant enhancement of VEGF expression or functional endothelial morphogenesis under the studied conditions.